Chief, Mucosal Immunology and Virology Unit (MIVU)
Stadtman Tenure-Track Investigator
Education:
Ph.D., Virology, 2013, Imperial College London, United Kingdom
Languages Spoken: Dutch
Biography
Dr. van Doremalen was born in the Netherlands and earned her Ph.D. in virology from Imperial College London, where she studied the cellular tropism and transmission of the influenza A virus. She subsequently joined the Laboratory of Virology at the NIAID Rocky Mountain Laboratories in Montana, focusing on emerging infectious diseases in high-containment settings. Her research centered on the ecology and countermeasures for Middle East respiratory syndrome coronavirus (MERS-CoV) and Nipah virus.
When SARS-CoV-2 emerged in late 2019, Dr. van Doremalen leveraged her expertise in MERS-CoV vaccine research to rapidly generate preclinical data for the Oxford-AstraZeneca COVID-19 vaccine, contributing to its global distribution and lifesaving impact. She joined NIAID as a Stadtman tenure-track investigator in 2024.
Currently, Dr. van Doremalen’s research focuses on uncovering the mechanisms of mucosal immune responses in the respiratory tract and understanding how these responses contribute to protection against respiratory viruses.